Elevated BUBR1 expression is associated with poor survival in early breast cancer patients: 15-year follow-up analysis

Journal of Histochemistry and Cytochemistry

Volumn 61, Issue 5, 2013, Pages 330-339

  Maciejczyk, Adam ^a   Szelachowska, Jolanta ^a,b   Czapiga, Bogdan ^b   Matkowski, Rafał ^a,b   Hałoń, Agnieszka ^b   Györffy, Balázs ^c   Surowiak, Paweł ^b  

^a 4th Department of Internal Medicine and Pulmonology   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Breast cancer; BUBR1; Prognostic biomarker

Indexed keywords

BUB1 RELATED PROTEIN; CYCLOPHOSPHAMIDE; FLUOROURACIL; MESSENGER RNA; METHOTREXATE; MONOCLONAL ANTIBODY; TAMOXIFEN; BUB1 SPINDLE CHECKPOINT PROTEIN; PROTEIN SERINE THREONINE KINASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DATA BASE; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; EARLY CANCER; FOLLOW UP; GENE EXPRESSION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TUMOR GENE; BREAST TUMOR; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN-SERINE-THREONINE KINASES; SURVIVAL ANALYSIS;

MLCS; MLOWN;

EID: 84879301920     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155413480148     Document Type: Article

References (21)

1. Bloom H., Richardson W. 1957. Histological grading and prognosis in breast cancer: study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 11(3):359-377.
2. Bolanos-Garcia VM, Blundell TL. 2011. BUB1 and BUBR1: multifaceted kinases of the cell cycle. Trends Biochem Sci. 36(3):141-150.
3. Chinthalapally R., Hiroshi Y, Yixin Y, Wei D. 2009. Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice. Carcinogenesis. 30(9):1469-1474.
4. Du J., Du Q, Zhang Y, Sajdik C, Ruan Y, Tian XX, Fang WG. 2011. Expression of cell-cycle regulatory proteins BUBR1, MAD2, Aurora A., cyclin A and cyclin E in invasive ductal breast carcinomas. Histol Histopathol. 26(6):761-768.
5. Elston C.W., Ellis IO. 1991. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19:403-410.
6. Ferlay J., Shin HR, Bray F, Forman C, Mathers C and Parkin DM. 2010. Globocan 2008 v1.2, Cancer incidence and mortality worldwide: IARC Cancerbase No. 10. Lyon, France: International Agency for Research on Cancer.
7. Frio T.R., Lavoie J, Hamel N, Geyer F, Kushner Y, Novak D, Wark L, Capelli C, Reis-Filho J, Mai S, et al. 2010. Homozygous BUB1B mutation and susceptibility to gastrointestinal neoplasia. N Engl J Med. 363:2628-2637.
8. Goldhirsch A., Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel members. 2009. Threshold for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol. 13:1319-1329.
9. Greene L.M., Campiani G, Lawler M, Williams DC, Zisterer DM. 2008. BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines. Mol Pharmacol. 73:419-430.
10. Györffy B., Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z. 2010. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat. 123:725-731.
11. Lee Y.K., Choi E, Kim MA, Park PG, Park NH, Lee H. 2009. BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers. Br J Cancer. 101:504-510.
12. Logarinho E., Bousbaa H. 2008. Kinetochore-microtubule interactions "in check" by Bub1, Bub3 and BubR1. Cell Cycle. 7(12):1763-1768.
13. Madden JL. 1965. Modified radical mastectomy. Surg Gynecol Obstet. 121:1221.
14. Nasir A., Chen DT, Gruidl M, Henderson-Jackson EB, Venkataramu C, McCarthy SM, McBride HL, Harris E, Khakpour N, Yeatman TJ. 2011. Novel molecular markers of malignancy in histologically normal and benign breast. Pathol Res Int. 2011:489064.
15. Nobuyuki W., Akira Y, Yohei M, Toshiharu Y, Hirotaka N, Nobuyasu S., Kenichi M, Katsuhiko M, Shohei H, Yasushi R, et al. 2008. Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature. Anticancer Res. 28:139-144.
16. Privette L.M., Weier JF, Nguyen HN, Yu X, Petty EM. 2008. Loss of CHFR in human mammary epithelial cells causes genomic instability by disrupting the mitotic spindle assembly checkpoint. Neoplasia. 10:643-652.
17. Remmele W., Stegner HE. 1987. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 8:138-140.
18. Scanlon E.F., Caprini JA. 1975. Modified radical mastectomy. Cancer. 35:710-713.
19. Shichiri M., Yoshinaga K, Hisatomi H, Sugihara K, Hirata Y. 2002. Genetic and epigenetic inactivation of mitotic checkpoint genes hBUB1 and hBUBR1 and their relationship to survival. Cancer Res. 62:13-17.
20. A, Stanisz, ed. 2007. Przyste{ogonek}pny kurs statystyki z zastosowaniem Statistica Pl na przykładach z medycyny. Kraków: Statsoft.
21. Weaver B., Cleveland D. 2007. Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res. 67:10103-10105.